0001209191-19-024814.txt : 20190416 0001209191-19-024814.hdr.sgml : 20190416 20190416184155 ACCESSION NUMBER: 0001209191-19-024814 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190416 FILED AS OF DATE: 20190416 DATE AS OF CHANGE: 20190416 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Countouriotis Athena CENTRAL INDEX KEY: 0001571469 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38871 FILM NUMBER: 19751892 MAIL ADDRESS: STREET 1: C/O AMBIT BIOSCIENCES CORPORATION STREET 2: 11080 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc. CENTRAL INDEX KEY: 0001595893 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463826166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 225 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-926-5251 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 225 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, Inc. DATE OF NAME CHANGE: 20181018 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, INC DATE OF NAME CHANGE: 20140106 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-04-16 0 0001595893 Turning Point Therapeutics, Inc. TPTX 0001571469 Countouriotis Athena C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, STE. 225 SAN DIEGO CA 92121 1 1 0 0 President & CEO Stock Option (right to buy) 3.20 2028-06-05 Common Stock 225723 D Stock Option (right to buy) 3.20 2028-06-05 Common Stock 75241 D Stock Option (righ to buy) 5.12 2028-11-05 Common Stock 989971 D Stock Option (right to buy) 7.43 2029-02-19 Common Stock 155844 D 25% of the shares vest on May 7, 2019 and 1/48th of the shares vest monthly thereafter over the next three years. 25% of the shares vest on June 29, 2019 and 1/48th of the shares vest monthly thereafter over the next three years. 25% of the shares vest on September 29, 2019, and 1/48th of the shares vest monthly thereafter over the next three years. 25% of the shares vest on February 12, 2020 and 1/48th of the shares vest monthly thereafter over the next three years. /s/ Athena Countouriotis 2019-04-09 EX-24.3_847910 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Brian Baker and Annette North of Turning Point Therapeutics, Inc. (the "Company"), signing individually, the undersigned's true and lawful attorney-in-fact and agent to: (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9th day of April, 2019. /s/ Athena Countouriotis, M.D.